Aspirin shows inferior efficacy in curbing blood clot risk in myeloma

09/11/2013 | MyelomaBeacon.com

A French study in the journal Thrombosis and Haemostasis found that aspirin was inferior to vitamin K antagonists and low-molecular weight heparin in preventing blood clots in myeloma patients taking Revlimid or thalidomide. The results suggest that clinicians prescribe low-molecular weight heparin or vitamin K antagonists to high-risk patients and that treatment should be continued as needed to address clotting risk, researchers said.

View Full Article in:

MyelomaBeacon.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consultant
Attest Health Care Advisors
Nationwide, SL_Nationwide
Biotechnology/Pharmaceutical Patent Attorney
Coats and Bennett PLLC
Cary, NC
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI